Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleGPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06196294 - 1. fázisTaking peopleGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198546 - 2/3. fázisTaking peopleTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Where
- Guanzhou
- Életkor
- 18 év and over
- People
- 200
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03755739 - 2. fázisTaking peopleTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 85 év
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04803318 - 1. fázisTaking peopleEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 85 év
- People
- 40
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04842812 - 1/2. fázisTaking peopleTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05187338 - 1. fázisTaking peoplePalliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Zhiyong Huang
See details and how to joinNCT06470256 - No phaseNot yet taking people in KínaCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
- Where
- Foshan, Guangzhou, Guanzhou
- Életkor
- 18 év to 75 év
- People
- 152
- Run by
- Zhujiang Hospital
See details and how to joinNCT06449846 - No phaseNot yet taking people in KínaCombining Chemoradiotherapy With Sintilimab in First-Line ICC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 19
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06447454 - 1. fázisTaking peopleITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
- Where
- Guangzhou, Luzhou
- Életkor
- 18 év to 80 év
- People
- 90
- Run by
- Institute of Automation, Chinese Academy of Sciences
See details and how to joinNCT06204835 - 1/2. fázisNot yet taking people in KínaFOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 62
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06409637 - 2. fázisTaking peopleCadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Where
- Changsha
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT06406634 - 4. fázisTaking peoplePrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Chen Xiaoping
See details and how to joinNCT06311929 - 2. fázisTaking peopleSintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 23
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06397222 - 3. fázisNot yet taking people in KínaPostoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 360
- Run by
- Tongji Hospital
See details and how to joinNCT06089369 - 2. fázisTaking peoplePhase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
- Where
- Beijing
- Életkor
- 18 év to 90 év
- People
- 30
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06389422 - 3. fázisTaking peopleLenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 196
- Run by
- Wen Tianfu
See details and how to joinNCT05738616 - 2. fázisTaking peopleChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 40
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06280508 - 2. fázisTaking peopleAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 111
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06360042 - 2. fázisTaking peoplePerioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
- Where
- Jinan
- Életkor
- 18 év and over
- People
- 20
- Run by
- Lei ZHAO
See details and how to joinNCT06296563 - 2. fázisTaking peopleA Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
- Where
- Fuzhou
- Életkor
- 18 év to 80 év
- People
- 57
- Run by
- Fujian Medical University
See details and how to joinNCT06363825 - 1. fázisTaking peopleCombination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06363006 - No phaseTaking peopleImmunotherapy for Hepatocellular Carcinoma
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 11 000
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06241326 - 1/2. fázisTaking peopleOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Where
- Beijing, Changchun, Changsha, Chengdu, Hangzhou, Lishui, Shanghai
- Életkor
- 18 év to 70 év
- People
- 105
- Run by
- OriCell Therapeutics Co., Ltd.
See details and how to joinNCT05652920 - 2. fázisTaking peopleCadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06215651